Exercise: A Novel Treatment for Obstructive Sleep Apnea

运动:阻塞性睡眠呼吸暂停的新疗法

基本信息

项目摘要

DESCRIPTION (provided by applicant): Obstructive sleep apnea (OSA) is a common sleep disorder, affecting approximately 10% of adults. The disorder is a public health threat, as OSA has been linked to cognitive impairment, impaired sleep quality, cardiovascular disease, diabetes and mortality. However, despite its harmful impact on numerous health outcomes, successful treatment options for OSA remain elusive. Surgery and nasal continuous positive airway pressure (nCPAP) therapy are the most common treatments, but these options are plagued by dismal success rates and low compliance rates, respectively. Exercise has been considered as a potential supplemental treatment option for OSA, primarily because of its weight loss effects. Surprisingly little investigation into this area has been undertaken, though. Consistent with the CDC Health Protection Goal of "Healthy People in Every Stage of Life," this proposal is designed with the objective of "preventing chronic diseases [i.e., the sequelae of OSA] and their consequences among adults." Specifically, the proposed study will investigate the efficacy of exercise as a complementary or alternative treatment for the treatment of OSA and its consequences. The study will utilize a randomized experimental design to assess the effect of a 8-week resistance and aerobic exercise program on the severity and complications of OSA. Specific Aim 1 is to evaluate the effect of exercise on the apnea-hypopnea index (AHI), the primary measure of OSA severity. Additionally, mediators of the effect of exercise on AHI will be evaluated. Because the effects of OSA on health outcomes are wide- ranging, Specific Aim 2 will evaluate the effect of exercise on a variety of OSA complications, including metabolic function, cognitive performance, daytime sleepiness, sleep quality, psychological health, systemic inflammation, and cardiovascular health. The results of this study will provide important and much needed information on whether exercise is an efficacious supplemental or alternative treatment option for individuals with OSA. Obstructive sleep apnea is a prevalent sleep disorder and emerging public health threat, with harmful consequences on cardiovascular health, metabolic functioning, cognition, and psychological health. Exercise has been understudied as a treatment option for attenuating the severity and complications of this disorder, especially since available treatment options are suboptimal. The proposed study will provide the first controlled evidence of the efficacy of exercise for the management of obstructive sleep apnea, and will shed light on whether exercise therapy can be advanced as an alternative or supplemental treatment option.
描述(由申请人提供):阻塞性睡眠呼吸暂停 (OSA) 是一种常见的睡眠障碍,影响大约 10% 的成年人。这种疾病是一种公共健康威胁,因为 OSA 与认知障碍、睡眠质量受损、心血管疾病、糖尿病和死亡率有关。然而,尽管 OSA 对许多健康结果产生有害影响,但 OSA 的成功治疗方案仍然难以捉摸。手术和经鼻持续气道正压通气 (nCPAP) 治疗是最常见的治疗方法,但这些选择分别因成功率低和依从率低而受到困扰。运动被认为是 OSA 的潜在补充治疗选择,主要是因为它具有减肥作用。但令人惊讶的是,对这一领域的调查却很少。与疾病预防控制中心“生命各个阶段的健康人”的健康保护目标相一致,该提案的目的是“预防成年人的慢性疾病[即阻塞性睡眠呼吸暂停的后遗症]及其后果”。具体来说,拟议的研究将调查运动作为治疗 OSA 的补充或替代疗法的功效及其后果。该研究将采用随机实验设计来评估为期 8 周的阻力和有氧运动计划对 OSA 严重程度和并发症的影响。具体目标 1 是评估运动对呼吸暂停低通气指数 (AHI) 的影响,该指数是 OSA 严重程度的主要衡量标准。此外,还将评估运动对 AHI 影响的中介因素。由于 OSA 对健康结果的影响广泛,具体目标 2 将评估运动对各种 OSA 并发症的影响,包括代谢功能、认知表现、白天嗜睡、睡眠质量、心理健康、全身炎症和心血管健康。这项研究的结果将提供重要且急需的信息,说明运动对于 OSA 患者是否是一种有效的补充或替代治疗选择。阻塞性睡眠呼吸暂停是一种普遍存在的睡眠障碍和新出现的公共卫生威胁,对心血管健康、代谢功能、认知和心理健康产生有害后果。运动作为减轻这种疾病的严重程度和并发症的治疗选择尚未得到充分研究,特别是因为现有的治疗选择并不理想。拟议的研究将为运动治疗阻塞性睡眠呼吸暂停的功效提供第一个对照证据,并将阐明运动疗法是否可以作为替代或补充治疗选择。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christopher Edward Kline其他文献

Christopher Edward Kline的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christopher Edward Kline', 18)}}的其他基金

Reducing sedentary behavior to improve sleep: an ancillary study to the RESET BP clinical trial
减少久坐行为以改善睡眠:RESET BP 临床试验的辅助研究
  • 批准号:
    9770022
  • 财政年份:
    2019
  • 资助金额:
    $ 3.78万
  • 项目类别:
Disentangling subclinical cardiovascular risk associated with insomnia, short sleep duration, and their combination
解开与失眠、睡眠时间短及其组合相关的亚临床心血管风险
  • 批准号:
    9808185
  • 财政年份:
    2019
  • 资助金额:
    $ 3.78万
  • 项目类别:
Reducing sedentary behavior to improve sleep: an ancillary study to the RESET BP clinical trial
减少久坐行为以改善睡眠:RESET BP 临床试验的辅助研究
  • 批准号:
    10375417
  • 财政年份:
    2019
  • 资助金额:
    $ 3.78万
  • 项目类别:
Reducing sedentary behavior to improve sleep: an ancillary study to the RESET BP clinical trial
减少久坐行为以改善睡眠:RESET BP 临床试验的辅助研究
  • 批准号:
    9899321
  • 财政年份:
    2019
  • 资助金额:
    $ 3.78万
  • 项目类别:
A Novel Risk Factor for Cardiovascular Disease: The Insomnia-Short Sleep Phenotyp
心血管疾病的新危险因素:失眠-睡眠不足表型
  • 批准号:
    8987442
  • 财政年份:
    2014
  • 资助金额:
    $ 3.78万
  • 项目类别:
A Novel Risk Factor for Cardiovascular Disease: The Insomnia-Short Sleep Phenotyp
心血管疾病的新危险因素:失眠-睡眠不足表型
  • 批准号:
    9197927
  • 财政年份:
    2014
  • 资助金额:
    $ 3.78万
  • 项目类别:
A Novel Risk Factor for Cardiovascular Disease: The Insomnia-Short Sleep Phenotyp
心血管疾病的新危险因素:失眠-睡眠不足表型
  • 批准号:
    8633831
  • 财政年份:
    2014
  • 资助金额:
    $ 3.78万
  • 项目类别:

相似国自然基金

Novel-miR-1134调控LHCGR的表达介导拟 穴青蟹卵巢发育的机制研究
  • 批准号:
  • 批准年份:
    2025
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
novel-miR75靶向OPR2,CA2和STK基因调控人参真菌胁迫响应的分子机制研究
  • 批准号:
    82304677
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
海南广藿香Novel17-GSO1响应p-HBA调控连作障碍的分子机制
  • 批准号:
    82304658
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
白术多糖通过novel-mir2双靶向TRADD/MLKL缓解免疫抑制雏鹅的胸腺程序性坏死
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
novel-miR-59靶向HMGAs介导儿童早衰症细胞衰老的作用及机制研究
  • 批准号:
  • 批准年份:
    2021
  • 资助金额:
    58 万元
  • 项目类别:
    面上项目
novel_circ_008138/rno-miR-374-3p/SFRP4调控Wnt信号通路参与先天性肛门直肠畸形发生的分子机制研究
  • 批准号:
    82070530
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA-novel-272通过靶向半乳糖凝集素3调控牙鲆肠道上皮细胞炎症反应的机制研究
  • 批准号:
    32002421
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目
m6A修饰介导的lncRNA WEE2-AS1转录后novel-pri-miRNA剪切机制在胶质瘤恶性进展中的作用研究
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    55 万元
  • 项目类别:
    面上项目
miRNA/novel_167靶向抑制Dmrt1的表达在红鳍东方鲀性别分化过程中的功能研究
  • 批准号:
    31902347
  • 批准年份:
    2019
  • 资助金额:
    25.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

ICF: A novel dual-target gene therapy for safe and efficacious treatment of chronic non-infectious uveitis
ICF:一种安全有效治疗慢性非感染性葡萄膜炎的新型双靶点基因疗法
  • 批准号:
    MR/Z50385X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Research Grant
A novel treatment for REBOA complications: Hydrogen gas inhalation therapy to alleviate oxidative stress due to ischemia-reperfusion injury
REBOA并发症的新型治疗方法:氢气吸入疗法减轻缺血再灌注损伤引起的氧化应激
  • 批准号:
    23K21458
  • 财政年份:
    2024
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Evaluating novel mutant-selective PDE4D PROTACs for the treatment of Acrodysostosis Type 2
评估新型突变选择性 PDE4D PROTAC 治疗 2 型肢节性骨质疏松症
  • 批准号:
    MR/Y003640/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Research Grant
Confirmation of therapeutic benefit of a novel metabolic disease treatment in female subjects
证实一种新型代谢性疾病治疗方法对女性受试者的治疗效果
  • 批准号:
    10104244
  • 财政年份:
    2024
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Launchpad
Development of novel treatment targeting the HGF/MET pathway in metastatic CRPC
针对转移性 CRPC 中 HGF/MET 通路的新型治疗方法的开发
  • 批准号:
    23K08737
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Aging of cardiac fibroblasts and heart failure: novel heart failure treatment through regeneration and transplantation of cardiac fibroblasts
心脏成纤维细胞的衰老和心力衰竭:通过心脏成纤维细胞的再生和移植治疗心力衰竭
  • 批准号:
    23K07526
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of a novel treatment targeting the immunosuppressive mechanism of MDSC for canine malignant melanoma
针对MDSC免疫抑制机制开发犬恶性黑色素瘤新疗法
  • 批准号:
    23K05561
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of novel strategy for treatment of cancer-evoked pain based on circadian clock machinery
基于生物钟机制开发治疗癌症引起的疼痛的新策略
  • 批准号:
    22KJ2424
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Elucidation of novel pathophysiology and development of treatment for heart failure using human iPS cell-derived 3D heart tissue
利用人 iPS 细胞衍生的 3D 心脏组织阐明新的病理生理学并开发心力衰竭治疗方法
  • 批准号:
    23K15140
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Rapid measurement of novel harm reduction housing on HIV risk, treatment uptake, drug use and supply
快速测量新型减害住房对艾滋病毒风险、治疗接受情况、毒品使用和供应的影响
  • 批准号:
    10701309
  • 财政年份:
    2023
  • 资助金额:
    $ 3.78万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了